UNSPSC 51386605: Diperodon/hydrocortisone/zinc oxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386605 Diperodon/hydrocortisone/zinc oxide is a Commodity code that state and local governments use to classify pharmaceutical and over-the-counter topical products, though recent opportunities show considerably broader purchasing activity than the code name alone suggests. State and local bodies are procuring generic multi-source pharmaceuticals, naloxone, drug deactivation systems, and OTC products through competitive bidding processes, cooperative purchasing agreements, and market-intelligence solicitations. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP), indicating that purchasing spans individual counties, state agencies, and regional cooperative vehicles that serve multiple jurisdictions.

Activity spans Florida, Texas, and Minnesota through at least the most recent cycle. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026 with response due July 26, 2023; the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs, posted April 3, 2026; and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with proposal due March 26, 2026. The MMCAP procurement requires suppliers to work through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), maintain cGMP and DSCSA compliance, carry $2 million to $5 million in insurance, and accept 3 percent administrative fees with performance penalties ranging from $200 to $1,500 per violation. The code shows active and recurring state and local procurement across health departments and cooperative purchasing bodies, though the recent opportunities span pharmaceutical products well beyond the specific topical formulation named in the code.